LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Becton Dickinson To Host Virtual 2025 Annual Meeting of Shareholders

January 07, 2025 | Last Trade: US$174.63 1.68 0.97

FRANKLIN LAKES, N.J., Jan. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2025 Annual Meeting of Shareholders (the "Annual Meeting") on Tuesday, January 28, 2025, at 1:00 p.m. (ET).

As described in the proxy materials for the Annual Meeting previously distributed, shareholders as of the close of business on December 9, 2024, or their duly authorized proxies, will be able to attend and participate in the Annual Meeting, vote their shares and ask questions by visiting https://meetnow.global/M5X7D4A. Guests may also access the Annual Meeting but in listen-only mode. No control number is required for guests.

A replay of the webcast will be available shortly after the Annual Meeting on the BD website at investors.bd.com for approximately one year from the date of the Annual Meeting.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Contacts:               

 

Media:                               

Investors:

Troy Kirkpatrick                   

Adam Reiffe

VP, Public Relations           

Sr. Director, Investor Relations

858.617.2361                       

201.847.6927        

This email address is being protected from spambots. You need JavaScript enabled to view it.       

This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page